Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease. / Bjerrum, Jacob Tveiten; Steenholdt, Casper; Ainsworth, Mark; Nielsen, Ole Haagen; Reed, Michelle A.C.; Atkins, Karen; Günther, Ulrich Leonhard; Hao, Fuhua; Wang, Yulan.

In: BMC Medicine, Vol. 15, No. 1, 184, 2017.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Bjerrum, JT, Steenholdt, C, Ainsworth, M, Nielsen, OH, Reed, MAC, Atkins, K, Günther, UL, Hao, F & Wang, Y 2017, 'Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease', BMC Medicine, vol. 15, no. 1, 184. https://doi.org/10.1186/s12916-017-0949-7

APA

Bjerrum, J. T., Steenholdt, C., Ainsworth, M., Nielsen, O. H., Reed, M. A. C., Atkins, K., ... Wang, Y. (2017). Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease. BMC Medicine, 15(1), [184]. https://doi.org/10.1186/s12916-017-0949-7

Vancouver

Bjerrum JT, Steenholdt C, Ainsworth M, Nielsen OH, Reed MAC, Atkins K et al. Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease. BMC Medicine. 2017;15(1). 184. https://doi.org/10.1186/s12916-017-0949-7

Author

Bjerrum, Jacob Tveiten ; Steenholdt, Casper ; Ainsworth, Mark ; Nielsen, Ole Haagen ; Reed, Michelle A.C. ; Atkins, Karen ; Günther, Ulrich Leonhard ; Hao, Fuhua ; Wang, Yulan. / Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease. In: BMC Medicine. 2017 ; Vol. 15, No. 1.

Bibtex

@article{91dbb1f7775d407d9b478b51bd66260d,
title = "Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease",
abstract = "Background: One-third of inflammatory bowel disease (IBD) patients show no response to infliximab (IFX) induction therapy, and approximately half of patients responding become unresponsive over time. Thus, identification of potential treatment response biomarkers are of great clinical significance. This study employs spectroscopy-based metabolic profiling of serum from patients with IBD treated with IFX and healthy subjects (1) to substantiate the use of spectroscopy as a semi-invasive diagnostic tool, (2) to identify potential biomarkers of treatment response and (3) to characterise the metabolic changes during management of patients with tumour necrosis factor-α inhibitors. Methods: Successive serum samples collected during IFX induction treatment (weeks 0, 2, 6 and 14) from 87 IBD patients and 37 controls were analysed by 1H nuclear magnetic resonance (NMR) spectroscopy. Data were analysed with principal components analysis and orthogonal projection to latent structures discriminant analysis using SIMCA-P+ v12 and MATLAB. Results: Metabolic profiles were significantly different between active ulcerative colitis and controls, active Crohn's disease and controls, and quiescent Crohn's disease and controls. Metabolites holding differential power belonged primarily to lipids and phospholipids with proatherogenic characteristics and metabolites in the pyruvate metabolism, suggestive of an intense inflammation-driven energy demand. IBD patients not responding to IFX were identified as a potentially distinct group based on their metabolic profile, although no applicable response biomarkers could be singled out in the current setting. Conclusion:1H NMR spectroscopy of serum samples is a powerful semi-invasive diagnostic tool in flaring IBD. With its use, we provide unique insights into the metabolic changes taking place during induction treatment with IFX. Of distinct clinical relevance is the identification of a reversible proatherogenic lipid profile in IBD patients with active disease, which partially explains the increased risk of cardiovascular disease associated with IBD.",
keywords = "Crohn's disease, Diagnostics, Metabolomics, Serum, Ulcerative colitis",
author = "Bjerrum, {Jacob Tveiten} and Casper Steenholdt and Mark Ainsworth and Nielsen, {Ole Haagen} and Reed, {Michelle A.C.} and Karen Atkins and G{\"u}nther, {Ulrich Leonhard} and Fuhua Hao and Yulan Wang",
year = "2017",
doi = "10.1186/s12916-017-0949-7",
language = "English",
volume = "15",
journal = "B M C Medicine",
issn = "1741-7015",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease

AU - Bjerrum, Jacob Tveiten

AU - Steenholdt, Casper

AU - Ainsworth, Mark

AU - Nielsen, Ole Haagen

AU - Reed, Michelle A.C.

AU - Atkins, Karen

AU - Günther, Ulrich Leonhard

AU - Hao, Fuhua

AU - Wang, Yulan

PY - 2017

Y1 - 2017

N2 - Background: One-third of inflammatory bowel disease (IBD) patients show no response to infliximab (IFX) induction therapy, and approximately half of patients responding become unresponsive over time. Thus, identification of potential treatment response biomarkers are of great clinical significance. This study employs spectroscopy-based metabolic profiling of serum from patients with IBD treated with IFX and healthy subjects (1) to substantiate the use of spectroscopy as a semi-invasive diagnostic tool, (2) to identify potential biomarkers of treatment response and (3) to characterise the metabolic changes during management of patients with tumour necrosis factor-α inhibitors. Methods: Successive serum samples collected during IFX induction treatment (weeks 0, 2, 6 and 14) from 87 IBD patients and 37 controls were analysed by 1H nuclear magnetic resonance (NMR) spectroscopy. Data were analysed with principal components analysis and orthogonal projection to latent structures discriminant analysis using SIMCA-P+ v12 and MATLAB. Results: Metabolic profiles were significantly different between active ulcerative colitis and controls, active Crohn's disease and controls, and quiescent Crohn's disease and controls. Metabolites holding differential power belonged primarily to lipids and phospholipids with proatherogenic characteristics and metabolites in the pyruvate metabolism, suggestive of an intense inflammation-driven energy demand. IBD patients not responding to IFX were identified as a potentially distinct group based on their metabolic profile, although no applicable response biomarkers could be singled out in the current setting. Conclusion:1H NMR spectroscopy of serum samples is a powerful semi-invasive diagnostic tool in flaring IBD. With its use, we provide unique insights into the metabolic changes taking place during induction treatment with IFX. Of distinct clinical relevance is the identification of a reversible proatherogenic lipid profile in IBD patients with active disease, which partially explains the increased risk of cardiovascular disease associated with IBD.

AB - Background: One-third of inflammatory bowel disease (IBD) patients show no response to infliximab (IFX) induction therapy, and approximately half of patients responding become unresponsive over time. Thus, identification of potential treatment response biomarkers are of great clinical significance. This study employs spectroscopy-based metabolic profiling of serum from patients with IBD treated with IFX and healthy subjects (1) to substantiate the use of spectroscopy as a semi-invasive diagnostic tool, (2) to identify potential biomarkers of treatment response and (3) to characterise the metabolic changes during management of patients with tumour necrosis factor-α inhibitors. Methods: Successive serum samples collected during IFX induction treatment (weeks 0, 2, 6 and 14) from 87 IBD patients and 37 controls were analysed by 1H nuclear magnetic resonance (NMR) spectroscopy. Data were analysed with principal components analysis and orthogonal projection to latent structures discriminant analysis using SIMCA-P+ v12 and MATLAB. Results: Metabolic profiles were significantly different between active ulcerative colitis and controls, active Crohn's disease and controls, and quiescent Crohn's disease and controls. Metabolites holding differential power belonged primarily to lipids and phospholipids with proatherogenic characteristics and metabolites in the pyruvate metabolism, suggestive of an intense inflammation-driven energy demand. IBD patients not responding to IFX were identified as a potentially distinct group based on their metabolic profile, although no applicable response biomarkers could be singled out in the current setting. Conclusion:1H NMR spectroscopy of serum samples is a powerful semi-invasive diagnostic tool in flaring IBD. With its use, we provide unique insights into the metabolic changes taking place during induction treatment with IFX. Of distinct clinical relevance is the identification of a reversible proatherogenic lipid profile in IBD patients with active disease, which partially explains the increased risk of cardiovascular disease associated with IBD.

KW - Crohn's disease

KW - Diagnostics

KW - Metabolomics

KW - Serum

KW - Ulcerative colitis

U2 - 10.1186/s12916-017-0949-7

DO - 10.1186/s12916-017-0949-7

M3 - Journal article

C2 - 29032767

AN - SCOPUS:85031408391

VL - 15

JO - B M C Medicine

JF - B M C Medicine

SN - 1741-7015

IS - 1

M1 - 184

ER -

ID: 185032674